A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation

BackgroundAlthough altered protocols that challenge conventional radiation fractionation have been tested in prospective clinical trials, we still have limited understanding of how to select the most appropriate fractionation schedule for individual patients. Currently, the prescription of definitive radiotherapy is based on the primary site and stage, without regard to patient-specific tumor or host factors that may influence outcome. We hypothesize that the proportion of radiosensitive proliferating cells is dependent on the saturation of the tumor carrying capacity. This may serve as a prognostic factor for personalized radiotherapy (RT) fractionation.MethodsWe introduce a proliferation saturation index (PSI), which is defined as the ratio of tumor volume to the host-influenced tumor carrying capacity. Carrying capacity is as a conceptual measure of the maximum volume that can be supported by the current tumor environment including oxygen and nutrient availability, immune surveillance and acidity. PSI is estimated from two temporally separated routine pre-radiotherapy computed tomography scans and a deterministic logistic tumor growth model. We introduce the patient-specific pre-treatment PSI into a model of tumor growth and radiotherapy response, and fit the model to retrospective data of four non-small cell lung cancer patients treated exclusively with standard fractionation. We then simulate both a clinical trial hyperfractionation protocol and daily fractionations, with equal biologically effective dose, to compare tumor volume reduction as a function of pretreatment PSI.ResultsWith tumor doubling time and radiosensitivity assumed constant across patients, a patient-specific pretreatment PSI is sufficient to fit individual patient response data (R2 = 0.98). PSI varies greatly between patients (coefficient of variation >128 %) and correlates inversely with radiotherapy response. For this study, our simulations suggest that only patients with intermediate PSI (0.45–0.9) are likely to truly benefit from hyperfractionation. For up to 20 % uncertainties in tumor growth rate, radiosensitivity, and noise in radiological data, the absolute estimation error of pretreatment PSI is <10 % for more than 75 % of patients.ConclusionsRoutine radiological images can be used to calculate individual PSI, which may serve as a prognostic factor for radiation response. This provides a new paradigm and rationale to select personalized RT dose-fractionation.

[1]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[2]  D Yan,et al.  An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[3]  Slav Yartsev,et al.  Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. , 2007, International journal of radiation oncology, biology, physics.

[4]  Randall K Ten Haken,et al.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. , 2009, International journal of radiation oncology, biology, physics.

[5]  P. Hahnfeldt,et al.  The Importance of Spatial Distribution of Stemness and Proliferation State in Determining Tumor Radioresponse , 2009 .

[6]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[7]  Sébastien Ourselin,et al.  Toward adaptive radiotherapy for head and neck patients: Feasibility study on using CT-to-CBCT deformable registration for "dose of the day" calculations. , 2014, Medical physics.

[8]  L. Hlatky,et al.  Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. , 2013, Cancer research.

[9]  J F Fowler,et al.  Non-small cell lung tumors repopulate rapidly during radiation therapy. , 2000, International journal of radiation oncology, biology, physics.

[10]  J. Folkman,et al.  SELF-REGULATION OF GROWTH IN THREE DIMENSIONS , 1973, The Journal of experimental medicine.

[11]  Peter Langguth,et al.  Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay - A comparative study , 2012, Radiation Oncology (London, England).

[12]  Y. Shibamoto,et al.  Radiobiology of Normal Lung Tissue and Lung Tumours , 2005 .

[13]  C. N. Coleman,et al.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. , 2014, Journal of thoracic disease.

[14]  J. M. Taylor,et al.  Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. , 1989, International journal of radiation oncology, biology, physics.

[15]  Philip Hahnfeldt,et al.  Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion , 2013, Interface Focus.

[16]  Paul Kinahan,et al.  A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET , 2015, Journal of The Royal Society Interface.

[17]  R. Macklis,et al.  Radiation Oncology BioMed Central Review The impact of functional imaging on radiation medicine , 2008 .

[18]  Yang Xie,et al.  Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity? , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  T. Dilling,et al.  Altered fractionation schedules in radiation treatment: a review. , 2014, Seminars in oncology.

[20]  R. Jain,et al.  Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.

[21]  Yudi Pawitan,et al.  Validation of a Radiosensitivity Molecular Signature in Breast Cancer , 2012, Clinical Cancer Research.

[22]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[23]  Mariana Guerrero,et al.  Radiobiological Modelling in Radiation Oncology , 2008 .

[24]  J. Freyer,et al.  Regulation of growth saturation and development of necrosis in EMT6/Ro multicellular spheroids by the glucose and oxygen supply. , 1986, Cancer research.

[25]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[26]  B. Warkentin,et al.  Radiobiological Modelling in Radiation Oncology , 2007 .

[27]  L. J. Park,et al.  Application of genetic algorithms to parameter estimation of bioprocesses , 2006, Medical and Biological Engineering and Computing.

[28]  Kristian Unger,et al.  Integrative radiation systems biology , 2014, Radiation Oncology.

[29]  Zhongxing Liao,et al.  What Would Be the Most Appropriate α/β Ratio in the Setting of Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer , 2013, BioMed research international.

[30]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[31]  Jae-Uk Jeong,et al.  Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group , 2015, Radiation Oncology.

[32]  References , 1971 .

[33]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[34]  Lynn Hlatky,et al.  Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  J. Fowler Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). , 2008, International journal of radiation oncology, biology, physics.

[36]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[37]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[38]  Priya Bhatnagar,et al.  Functional imaging for radiation treatment planning, response assessment, and adaptive therapy in head and neck cancer. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[39]  Ping Wang,et al.  A Mathematical Model of Tumor Volume Changes during Radiotherapy , 2013, TheScientificWorldJournal.

[40]  A. Kjær,et al.  Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study , 2014, Radiation oncology.

[41]  J. Fowler The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[42]  Hongxing Yang,et al.  Energy and Environment: Challenges and Achievements in Rapid Urbanization , 2013, The Scientific World Journal.